📈 Stock
I spoke with David Hung, M.D. earlier in November at Jefferies 2025. Two weeks later, Nuvation Bio's stock has pumped over 70%.
Nuvation is gaining real momentum after its first FDA approval, with IBTROZI now treating a growing number of patients with ROS1-positive lung cancer.
Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·
